2 results
Approved WMOCompleted
To assess the impact of treatment with Lanreotide versus current standard of treatment on output reduction in patients with high output enterocutaneous fistula or high-output stoma.
Approved WMOPending
The primary objectives of this trial are:• Part 1 (dose escalation): To evaluate the safety of BYON4228 alone and in combinationwith rituximab to determine the maximum tolerated dose (MTD), or optimal biological dose(OBD) if the MTD is not reached,…